Skip to main content
main-content

08-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: The ABILITY-3 trial

Walter Maksymowych comments on the ABILITY-3 trial results showing that continued adalimumab treatment is important for the maintenance of remission among patients with nonradiographic axial spondyloarthritis.

Read the accompanying news story

Please log in to get access to this content

image credits